Teva Pharmaceutical Q4 earnings $683 millionChristian Fernsby ▼ | February 12, 2020
Teva Pharmaceutical posted fourth quarter adjusted earnings of $683 million vs. $543 million in the comparable year earlier period.
Teva Pharmaceutical Total sales were $4.47 billion for the quarter
Topics: Teva Pharmaceutical
Sales of its multiple sclerosis drug Copaxone came in at $387 million, above estimates of $352.8 million, while sales of Austedo, used to treat Huntington’s disease and tardive dyskinesia, came in at $136 million vs. estimates of $111.8 million. ■